Efficacy and safety of PD-1 monoclonal antibody combined with interferon-alpha 1b and anlotinib hydrochloride as the second-line therapy in patients with unresectable advanced melanoma: A retrospective study.

Bolun ZhaoMengyu ZhangJingyi TangDaopei ZouFang LiuQiong ShiTianwen GaoChunying Li Guannan Zhu

Published in: Cancer medicine (2024)

PD-1 monoclonal antibody plus interferon-alpha 1b plus anlotinib showed acceptable tolerability and anticancer benefits in Chinese metastatic melanoma patients as a second-line therapy.

Keyphrases

monoclonal antibody
end stage renal disease
ejection fraction
dendritic cells
newly diagnosed
chronic kidney disease
prognostic factors
stem cells
clinical trial
randomized controlled trial
squamous cell carcinoma
patient reported outcomes
liver metastases